Your current region: US

Management Team

Page Header Image

Ron Stubbers, MBA

Ron Stubbers, MBA, is President of InGeneron focusing on the company’s product development, engineering, quality and regulatory activities. Mr. Stubbers has over 25 years of experience in operations, engineering and management of quality and regulatory affairs, product development and design and manufacturing engineering. Throughout his career Mr. Stubbers has contributed to the development and expansion of companies through organic growth and M&A.

Fabian Alt, M.Sc.
Chief Financial Officer

Fabian Alt, M.Sc., is Chief Financial Officer of InGeneron. Previously, he worked at Goldman Sachs in the Investment Banking Division in London. His experience extends across more than 20 completed capital market and M&A transactions, including several equity capital offerings and IPOs with >$500m deal value. Mr. Alt holds a M.Sc. Finance from the London School of Economics and Political Science (LSE), earned an Honors Master in Technology Management from the TU Munich/LMU Munich and received a Diploma/M.Sc. in Physics after studying at TU Munich and research stays at the Max-Planck-Institute for Quantum Optics and Massachusetts Institute of Technology (MIT).

Christoph Neyer, Dipl.-Ing.
Director Business Development

Christoph Neyer is Director Business Development of InGeneron. Previously he worked in the consulting industry at Bain & Company and is experienced in corporate full potential programs and mergers & acquisitions with focus on organizational restructuring, market entry strategies and sales force effectiveness. Mr. Neyer studied at TU Munich and Columbia Business School and was a holder of the Fulbright Scholarship.


Glenn Winnier, Ph.D.
Chief Science Officer

Glenn Winnier, Ph.D., is Chief Science Officer of InGeneron. Dr. Winnier has over 15 years of experience in scientific leadership and a proven track record in the design of studies which have led to the successful commercialization of novel therapeutics. Previously, he worked for Memorial Hermann, Houston Methodist Research Institute, Opexa Therapeutics, and Lexicon Genetics where he gained experience in disciplines ranging from the development of intellectual property to regulatory affairs, cGMP manufacturing, and clinical trial management. Glenn Winnier holds a Ph.D. in cell biology from Vanderbilt University.